A Long Noncoding RNA Signature That Predicts Pathological Complete Remission Rate Sensitively in Neoadjuvant Treatment of Breast Cancer.

ABSTRACT: BACKGROUND:Mounting evidence suggests that long noncoding RNAs (lncRNAs) are closely related to pathological complete response (pCR) in neoadjuvant treatment of breast cancer. Here, we construct lncRNA associated models to predict pCR rate. METHODS:LncRNA expression profiles of breast cancer patients treated with neoadjuvant chemotherapy (NAC) were obtained from Gene Expression Omnibus by repurposing existing microarray data. The prediction model was firstly built by analyzing the correlation between pCR and lncRNA expression in the discovery dataset GSE 25066 (n=488). Another three independent datasets, GSE20194 (n=278), GSE20271 (n=178), and GSE22093 (n=97), were integrated as the validation cohort to assess the prediction efficiency. RESULTS:A novel lncRNA signature (LRS) consisting of

SUBMITTER: Wang G 

PROVIDER: S-EPMC5671410 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature